First Patient Enrolled in Phase 2a Trial of Engensis
The first patient has been enrolled in a Phase 2a clinical trial investigating Helixmith’s gene therapy Engensis (VM202) for the…
Articles by Patricia Inácio, PhD
#MDA2021 – Rare WWOX Mutations in Patients Affect Mitochondria of Cells
Editor’s note: The ALS News Today team is providing in-depth coverage of the 2021 MDA Virtual Clinical and Scientific…
Canada Approves Xeomin for Excessive Drooling, Common in ALS Patients
Canadian authorities have approved Xeomin (incobotulinumtoxinA) for the treatment of chronic sialorrhea, or excessive drooling, associated with neurological diseases…
Dosing Begins in Phase 2 Study of Pegcetacoplan in ALS Patients
A first patient has been dosed in the Phase 2 trial investigating pegcetacoplan (APL-2), Apellis Pharmaceuticals‘ candidate therapy…
50K-signature Petition Calling for Swift Approval of AMX0035 Given FDA, Amylyx
The ALS Association and I AM ALS have filed a petition with the U.S. Food and Drug Administration (FDA), calling on the…
Scribe, Biogen Partner to Develop Gene Therapy for ALS, Other Neurological Diseases
Scribe Therapeutics and Biogen, a biotechnology company focused on neurological diseases, have established a research partnership to develop…
Dosing Begins in Phase 2a Study of ALZT-OP1a for Mild-to-Moderate ALS
The first patient has been dosed in a Phase 2a clinical trial evaluating the safety and effectiveness of ALZT-OP1a, a…
ALS Community Invited to Join Petition Calling on FDA to Approve AMX0035
The ALS Association and I AM ALS have opened a petition calling for the earliest possible approval of Amylyx’s…
Phase 3 Study of Oral Edaravone for ALS Resumes Patient Enrollment
The Phase 3 clinical trial testing an oral suspension formulation of edaravone for amyotrophic lateral sclerosis (ALS) has resumed dosing…
New ALS Chip Model Closely Mimics Disease, May Aid Research
Researchers report having created a new human-on-a-chip model, one able to more accurately simulate the clinical features of amyotrophic…